| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $58M |
Buys | $102,400 | 1 | 100 |
Sells | $0 | 0 | 0 |
| Berg Aaron | President and CEO | 1 | $102,400 | 0 | $0 | $102,400 |
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Over the last 12 months, insiders at Amarin Corporation plc have bought $102,400 and sold $0 worth of Amarin Corporation plc stock.
On average, over the past 5 years, insiders at Amarin Corporation plc have bought $174,734 and sold $5.19M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Berg Aaron (President and CEO) — $102,400.
The last purchase of 160,000 shares for transaction amount of $102,400 was made by Berg Aaron (President and CEO) on 2024‑08‑02.
| 2024-08-02 | Berg Aaron | President and CEO | 160,000 0.0389% | $0.64 | $102,400 | -13.59% | ||
| 2024-01-22 | Holt Patrick | President and CEO | 14,426 0.0033% | $1.09 | $15,724 | -39.30% | ||
| 2023-12-12 | Sale | Ketchum Steven B | Chief Scientific Officer | 34,131 0.0084% | $0.79 | $26,963 | -0.54% | |
| 2023-08-16 | Holt Patrick | President and CEO | 300,000 0.0723% | $1.04 | $312,315 | -18.77% | ||
| 2022-06-13 | WOLD OLSEN PER | 55,000 0.0137% | $1.69 | $92,730 | -21.76% | |||
| 2021-12-15 | Zakrzewski Joseph S | director | 2,000 0.0005% | $3.15 | $6,310 | -52.31% | ||
| 2021-12-14 | Zakrzewski Joseph S | director | 10,000 0.0025% | $3.27 | $32,689 | -52.00% | ||
| 2021-08-12 | Sale | Kalb Michael Wayne | SVP and CFO | 120,000 0.0282% | $5.25 | $630,240 | -41.05% | |
| 2021-06-04 | STACK DAVID M | director | 10,000 0.0026% | $4.54 | $45,350 | -17.42% | ||
| 2021-06-03 | STACK DAVID M | director | 5,000 0.0013% | $4.62 | $23,115 | -19.61% | ||
| 2021-02-01 | Sale | Ketchum Steven B | Chief Scientific Officer | 435,456 0.11% | $8.06 | $3.51M | -39.85% | |
| 2021-01-27 | Sale | Ketchum Steven B | Chief Scientific Officer | 843,258 0.2332% | $8.01 | $6.76M | -33.52% | |
| 2020-11-30 | STACK DAVID M | director | 50,000 0.0125% | $4.86 | $243,035 | +1.61% | ||
| 2020-11-11 | Sale | THERO JOHN F | President and CEO | 827,130 0.2094% | $4.07 | $3.36M | +22.63% | |
| 2020-11-10 | Sale | THERO JOHN F | President and CEO | 307,680 0.0792% | $4.13 | $1.27M | +22.63% | |
| 2020-03-04 | Sale | THERO JOHN F | President and CEO | 400,000 0.1106% | $15.99 | $6.4M | -58.77% | |
| 2020-01-03 | Sale | Zakrzewski Joseph S | director | 600,000 0.0965% | $12.17 | $7.3M | -67.88% | |
| 2019-12-16 | Sale | Berg Aaron | CHIEF COMMERCIAL OFFICER | 86,506 0.02% | $19.03 | $1.65M | -70.15% | |
| 2019-12-16 | Sale | Zakrzewski Joseph S | director | 200,000 0.0424% | $17.42 | $3.48M | -70.15% | |
| 2019-12-16 | Sale | Kalb Michael Wayne | SVP and CFO | 50,000 0.0142% | $23.36 | $1.17M | -70.15% |
| Berg Aaron | President and CEO | 805380 3.8894% | $8.95M | 1 | 4 | |
| SOFINNOVA VENTURE PARTNERS VII L P | 10 percent owner | 8513388 41.1136% | $94.58M | 0 | 7 | |
| HEALY JAMES | director | 5513388 26.6257% | $61.25M | 0 | 4 | |
| THERO JOHN F | President and CEO | 2739000 13.2274% | $30.43M | 6 | 9 | +65.82% |
| Abingworth LLP | 10 percent owner | 1599168 7.7228% | $17.77M | 0 | 11 | |
| Ketchum Steven B | Chief Scientific Officer | 566100 2.7339% | $6.29M | 0 | 21 | |
| Holt Patrick | President and CEO | 314426 1.5185% | $3.49M | 2 | 0 | <0.0001% |
| Kalb Michael Wayne | SVP and CFO | 205010 0.9901% | $2.28M | 0 | 8 | |
| Zakrzewski Joseph S | director | 196547 0.9492% | $2.18M | 3 | 16 | <0.0001% |
| WOLD OLSEN PER | 149000 0.7196% | $1.66M | 1 | 0 | <0.0001% | |
| STACK DAVID M | director | 40000 0.1932% | $444,400.00 | 3 | 4 | <0.0001% |
| Kennedy Joseph T | General Counsel | 31260 0.151% | $347,298.60 | 0 | 27 | |
| VAN HEEK G JAN | director | 14168 0.0684% | $157,406.48 | 0 | 3 | |
| Farrell Michael James | Controller | 6037 0.0292% | $67,071.07 | 1 | 0 | +140.48% |
| ORBIMED ADVISORS LLC | director | 5700 0.0275% | $63,327.00 | 0 | 21 | |
| GORDON CARL L | director | 5700 0.0275% | $63,327.00 | 0 | 21 | |
| SEDLACK STUART D | Senior Vice President | 0 0% | $0 | 0 | 1 | |
| Ekman Lars | director | 0 0% | $0 | 1 | 5 | <0.0001% |
| Ahlholm Frederick W | Vice President Finance | 0 0% | $0 | 0 | 2 | |
| Soni Paresh | SVP and Head of Development | 0 0% | $0 | 0 | 2 | |
| Peterson Kristine | director | 0 0% | $0 | 0 | 1 | |
| Huff Paul | Chief Commercial Officer | 0 0% | $0 | 0 | 6 |
$7,224,762 | 91 | -8.21% | $222.52M | |
$860,541,348 | 82 | -5.10% | $207.01M | |
$613,304,943 | 46 | 11.85% | $214.22M | |
$144,247,213 | 29 | 10.15% | $255.02M | |
$46,858,891 | 18 | -11.58% | $208.34M | |
$2,484,989 | 17 | -17.86% | $236.55M | |
Amarin Corporation plc (AMRN) | $1,345,573 | 16 | 15.45% | $230.05M |
$57,263,116 | 11 | -8.37% | $253.73M | |
$18,262,420 | 10 | 29.82% | $224.38M | |
$58,981,940 | 10 | 32.58% | $230.4M | |
$334,190 | 8 | 33.75% | $232.23M | |
$8,286,963 | 6 | 3.09% | $225.64M | |
$51,588,185 | 5 | 19.18% | $242.1M | |
$79,238,118 | 4 | -26.47% | $228.67M | |
$12,010,220 | 4 | -72.15% | $225.65M | |
$4,888,000 | 3 | -20.50% | $230.77M | |
$149,309 | 3 | 6.07% | $214.5M | |
$102,796 | 1 | -21.40% | $248.18M | |
$879,499 | 1 | 28.50% | $234.66M |
| Increased Positions | 48 | +23.76% | 2M | +45.95% |
| Decreased Positions | 70 | -34.65% | 300,041 | -8.43% |
| New Positions | 12 | New | 16,186 | New |
| Sold Out Positions | 29 | Sold Out | 47,329 | Sold Out |
| Total Postitions | 180 | -10.89% | 5M | +37.52% |
| Sarissa Capital Management Lp | $13,556.00 | 0.3% | 1.24M | 0 | 0% | 2024-12-31 |
| Kynam Capital Management, Lp | $6,772.00 | 0.15% | 620,731 | 0 | 0% | 2024-12-31 |
| Morgan Stanley | $2,404.00 | 0.05% | 220,321 | +93,033 | +73.09% | 2024-12-31 |
| Waterfront Wealth Inc. | $1,372.00 | 0.03% | 125,731 | +1,643 | +1.32% | 2025-03-31 |
| Scp Investment, Lp | $1,364.00 | 0.03% | 125,000 | 0 | 0% | 2024-12-31 |
| Two Sigma Investments, Lp | $1,186.00 | 0.03% | 108,687 | -10,314 | -8.67% | 2024-12-31 |
| Acadian Asset Management Llc | $974.00 | 0.02% | 89,290 | +76,139 | +578.96% | 2024-12-31 |
| Kornitzer Capital Management Inc /Ks | $962.00 | 0.02% | 88,200 | +83,960 | +1,980.19% | 2025-03-31 |
| Two Sigma Advisers, Lp | $949.00 | 0.02% | 86,965 | -11,835 | -11.98% | 2024-12-31 |
| Longitude (Cayman) Ltd. | $884.00 | 0.02% | 81,000 | -37,500 | -31.65% | 2024-12-31 |